Amgen and Ortho Bio settle antitrust suit
US biotechnology major Amgen has settled its antitrust litigation with Ortho Biotech, a unit of health care major Johnson & Johnson, for $200.0 million, but does not recognize any wrongdoing.
Ortho Biotech expects to record an after-tax sum of $120.0 million in the third quarter of this year. In return, the company will dismiss the pending litigation against Amgen in the New Jersey District Court with prejudice.
New Jersey-based Ortho had argued in the 2005 law suit that the way that Amgen bundled sales of its cancer therapy drugs forced cancer clinics in the USA to buy Amgen's Aranesp (darbepoetin alfa) rather than its own equivalent, Procrit (epoetin alfa).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze